269 related articles for article (PubMed ID: 13129388)
1. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
2. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
4. Development and activities of a new melphalan prodrug designed for tumor-selective activation.
Kerr DE; Li Z; Siemers NO; Senter PD; Vrudhula VM
Bioconjug Chem; 1998; 9(2):255-9. PubMed ID: 9548542
[TBL] [Abstract][Full Text] [Related]
5. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.
Kerr DE; Vrudhula VM; Svensson HP; Siemers NO; Senter PD
Bioconjug Chem; 1999; 10(6):1084-9. PubMed ID: 10563779
[TBL] [Abstract][Full Text] [Related]
6. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT.
Roberge M; Estabrook M; Basler J; Chin R; Gualfetti P; Liu A; Wong SB; Rashid MH; Graycar T; Babé L; Schellenberger V
Protein Eng Des Sel; 2006 Apr; 19(4):141-5. PubMed ID: 16436454
[TBL] [Abstract][Full Text] [Related]
7. Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase.
Goshorn SC; Svensson HP; Kerr DE; Somerville JE; Senter PD; Fell HP
Cancer Res; 1993 May; 53(9):2123-7. PubMed ID: 8481914
[TBL] [Abstract][Full Text] [Related]
8. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
9. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
10. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
[TBL] [Abstract][Full Text] [Related]
11. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
12. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
14. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
15. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
Alderson RF; Toki BE; Roberge M; Geng W; Basler J; Chin R; Liu A; Ueda R; Hodges D; Escandon E; Chen T; Kanavarioti T; Babé L; Senter PD; Fox JA; Schellenberger V
Bioconjug Chem; 2006; 17(2):410-8. PubMed ID: 16536473
[TBL] [Abstract][Full Text] [Related]
20. [Construction and expression of single chain Fv antibody against human bladder carcinoma].
Zhang M; Yu L; Huang H
Zhonghua Wai Ke Za Zhi; 2001 Oct; 39(10):792-5. PubMed ID: 16201198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
